Literature DB >> 34993939

Isolation and Maintenance of Tumor-Infiltrating Lymphocytes for Translational and Clinical Applications: Established Methods and New Developments.

Orenthial J Fulbright1, Marie-Andrée Forget1, Cara Haymaker1, Chantale Bernatchez2.   

Abstract

Adoptive cell transfer (ACT) of in vitro expanded tumor-infiltrating lymphocytes (TIL) for the treatment of patients with advanced stages of metastatic melanoma remains one of the most beneficial therapies eliciting long-lasting responses. Methods and protocols used to expand TIL have evolved over time, utilizing different culture devices and other tools, to streamline and maximize the end product in both numbers and quality. Summarized in this chapter are the latest protocols used in the TIL program at MDACC.
© 2022. The Author(s).

Entities:  

Keywords:  Adoptive cell therapy (ACT ); Cell culture; Cytotoxic T-lymphocytes; Immunotherapy; Rapid expansion protocol (REP ); Tumor-infiltrating lymphocytes (TIL)

Mesh：

Year:  2022        PMID： 34993939     DOI： 10.1007/978-1-0716-2014-4_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  12 in total

1.  4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.

Authors:  Michiko Harao; Marie-Andrée Forget; Jason Roszik; Hui Gao; Gildy V Babiera; Savitri Krishnamurthy; Jessica A Chacon; Shumin Li; Elizabeth A Mittendorf; Sarah M DeSnyder; Korrene F Rockwood; Chantale Bernatchez; Naoto T Ueno; Laszlo G Radvanyi; Luis Vence; Cara Haymaker; James M Reuben
Journal:  Cancer Immunol Res       Date:  2017-05-04       Impact factor: 11.151

2.  Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Authors:  Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

Review 3.  Disorders of the tarsus in the dog. I.

Authors:  L C Vaughan
Journal:  Br Vet J       Date:  1987 Sep-Oct

4.  4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

Authors:  Donastas Sakellariou-Thompson; Marie-Andrée Forget; Caitlin Creasy; Vincent Bernard; Li Zhao; Young Uk Kim; Mark W Hurd; Naohiro Uraoka; Edwin Roger Parra; Ya'an Kang; Christopher A Bristow; Jaime Rodriguez-Canales; Jason B Fleming; Gauri Varadhachary; Milind Javle; Michael J Overman; Hector A Alvarez; Timothy P Heffernan; Jianhua Zhang; Patrick Hwu; Anirban Maitra; Cara Haymaker; Chantale Bernatchez
Journal:  Clin Cancer Res       Date:  2017-09-25       Impact factor: 12.531

5.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.

Authors:  Jessica Ann Chacon; Amod A Sarnaik; Jie Qing Chen; Caitlin Creasy; Charuta Kale; John Robinson; Jeffrey Weber; Patrick Hwu; Shari Pilon-Thomas; Laszlo Radvanyi
Journal:  Clin Cancer Res       Date:  2014-12-03       Impact factor: 12.531

7.  CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.

Authors:  Mark E Dudley; Colin A Gross; Michelle M Langhan; Marcos R Garcia; Richard M Sherry; James C Yang; Giao Q Phan; Udai S Kammula; Marybeth S Hughes; Deborah E Citrin; Nicholas P Restifo; John R Wunderlich; Peter A Prieto; Jenny J Hong; Russell C Langan; Daniel A Zlott; Kathleen E Morton; Donald E White; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2010-07-28       Impact factor: 12.531

8.  Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.

Authors:  René J Tavera; Marie-Andrée Forget; Young Uk Kim; Donastas Sakellariou-Thompson; Caitlin A Creasy; Ankit Bhatta; Orenthial J Fulbright; Renjith Ramachandran; Shawne T Thorsen; Esteban Flores; Arely Wahl; Audrey M Gonzalez; Christopher Toth; Seth Wardell; Rahmatu Mansaray; Laszlo G Radvanyi; Dan S Gombos; Sapna P Patel; Patrick Hwu; Rodabe N Amaria; Chantale Bernatchez; Cara Haymaker
Journal:  J Immunother       Date:  2018 Nov/Dec       Impact factor: 4.456

9.  Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.

Authors:  Michal J Besser; Ronnie Shapira-Frommer; Orit Itzhaki; Avraham J Treves; Douglas B Zippel; Daphna Levy; Adva Kubi; Noa Shoshani; Dragoslav Zikich; Yaara Ohayon; Daniel Ohayon; Bruria Shalmon; Gal Markel; Ronit Yerushalmi; Sara Apter; Alon Ben-Nun; Eytan Ben-Ami; Avichai Shimoni; Arnon Nagler; Jacob Schachter
Journal:  Clin Cancer Res       Date:  2013-05-20       Impact factor: 12.531

10.  Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor.

Authors:  Robert P T Somerville; Laura Devillier; Maria R Parkhurst; Steven A Rosenberg; Mark E Dudley
Journal:  J Transl Med       Date:  2012-04-04       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.